| Primary |
| Atrial Fibrillation |
37.6% |
| Product Used For Unknown Indication |
10.2% |
| Arrhythmia |
9.9% |
| Hypertension |
7.6% |
| Drug Use For Unknown Indication |
6.2% |
| Atrial Flutter |
4.8% |
| Cardiac Failure |
3.7% |
| Cardiac Disorder |
2.9% |
| Ventricular Tachycardia |
2.2% |
| Prophylaxis |
1.9% |
| Hypothyroidism |
1.5% |
| Osteoarthritis |
1.4% |
| Hypercholesterolaemia |
1.4% |
| Depression |
1.3% |
| Tachycardia |
1.3% |
| Myocardial Infarction |
1.3% |
| Thrombosis Prophylaxis |
1.3% |
| Essential Hypertension |
1.2% |
| Supraventricular Tachycardia |
1.1% |
| Anticoagulant Therapy |
1.1% |
|
| Pulmonary Fibrosis |
7.8% |
| Lung Disorder |
7.0% |
| Renal Failure |
7.0% |
| Hyperthyroidism |
6.6% |
| International Normalised Ratio Increased |
6.4% |
| Weight Decreased |
6.2% |
| Drug Interaction |
6.0% |
| Syncope |
5.5% |
| Torsade De Pointes |
5.1% |
| Vomiting |
5.1% |
| Hypothyroidism |
4.9% |
| Renal Failure Acute |
4.9% |
| Pulmonary Toxicity |
4.5% |
| Interstitial Lung Disease |
3.7% |
| Pleural Effusion |
3.5% |
| Tremor |
3.5% |
| Malaise |
3.3% |
| Rectal Haemorrhage |
3.1% |
| Thrombocytopenia |
3.1% |
| Respiratory Failure |
2.7% |
|
| Secondary |
| Atrial Fibrillation |
23.4% |
| Drug Use For Unknown Indication |
20.7% |
| Product Used For Unknown Indication |
17.0% |
| Hypertension |
8.6% |
| Arrhythmia |
7.3% |
| Atrial Flutter |
3.6% |
| Cardiac Failure |
3.3% |
| Prophylaxis |
2.4% |
| Depression |
1.6% |
| Ill-defined Disorder |
1.5% |
| Essential Hypertension |
1.4% |
| Type 2 Diabetes Mellitus |
1.3% |
| Cardiac Disorder |
1.2% |
| Hypothyroidism |
1.2% |
| Ventricular Tachycardia |
0.9% |
| Chronic Obstructive Pulmonary Disease |
0.9% |
| Diabetes Mellitus |
0.9% |
| Rheumatoid Arthritis |
0.9% |
| Infection |
0.9% |
| Hypercholesterolaemia |
0.8% |
|
| Interstitial Lung Disease |
11.1% |
| Renal Failure |
9.2% |
| Renal Failure Acute |
8.8% |
| Vomiting |
6.4% |
| Thrombocytopenia |
6.0% |
| Hyperthyroidism |
5.6% |
| Rhabdomyolysis |
5.1% |
| International Normalised Ratio Increased |
4.7% |
| Torsade De Pointes |
4.5% |
| Malaise |
4.1% |
| Weight Increased |
3.9% |
| Toxic Skin Eruption |
3.8% |
| Hypothyroidism |
3.6% |
| Pneumonia |
3.6% |
| Pulmonary Fibrosis |
3.6% |
| Jaundice |
3.4% |
| Weight Decreased |
3.4% |
| Sinus Bradycardia |
3.2% |
| Syncope |
3.2% |
| Transaminases Increased |
3.0% |
|
| Concomitant |
| Product Used For Unknown Indication |
26.8% |
| Drug Use For Unknown Indication |
21.7% |
| Atrial Fibrillation |
11.6% |
| Hypertension |
9.8% |
| Arrhythmia |
3.3% |
| Prophylaxis |
3.0% |
| Cardiac Failure |
2.9% |
| Pain |
2.8% |
| Diabetes Mellitus |
1.9% |
| Osteoporosis |
1.8% |
| Cardiac Disorder |
1.6% |
| Type 2 Diabetes Mellitus |
1.5% |
| Rheumatoid Arthritis |
1.5% |
| Multiple Myeloma |
1.5% |
| Thrombosis Prophylaxis |
1.5% |
| Depression |
1.4% |
| Ill-defined Disorder |
1.4% |
| Acute Myocardial Infarction |
1.4% |
| Sepsis |
1.3% |
| Unevaluable Event |
1.3% |
|
| Renal Failure Acute |
18.9% |
| Vomiting |
10.4% |
| Renal Failure |
9.9% |
| Thrombocytopenia |
9.0% |
| International Normalised Ratio Increased |
6.1% |
| Weight Decreased |
3.8% |
| Toxic Skin Eruption |
3.5% |
| Death |
3.3% |
| Sepsis |
3.3% |
| Syncope |
3.3% |
| Ventricular Tachycardia |
3.3% |
| Hyponatraemia |
3.2% |
| Tremor |
3.2% |
| Hypotension |
3.1% |
| Fall |
2.8% |
| Gastrointestinal Haemorrhage |
2.8% |
| Somnolence |
2.7% |
| Diarrhoea |
2.6% |
| Anaemia |
2.5% |
| Malaise |
2.5% |
|
| Interacting |
| Atrial Fibrillation |
28.7% |
| Product Used For Unknown Indication |
9.9% |
| Atrial Flutter |
9.8% |
| Cardiac Failure |
8.0% |
| Drug Use For Unknown Indication |
7.4% |
| Hypertension |
6.2% |
| Depression |
4.4% |
| Hypercholesterolaemia |
2.8% |
| Pneumonia |
2.8% |
| Arrhythmia |
2.6% |
| Bone Marrow Failure |
2.6% |
| Pain |
1.9% |
| Infection |
1.8% |
| Arrhythmia Supraventricular |
1.7% |
| Parkinson's Disease |
1.7% |
| Prophylaxis |
1.7% |
| Renal Failure Chronic |
1.7% |
| Thrombosis Prophylaxis |
1.7% |
| Candidiasis |
1.4% |
| Ischaemic Cardiomyopathy |
1.4% |
|
| Drug Interaction |
22.7% |
| International Normalised Ratio Increased |
12.7% |
| Torsade De Pointes |
8.7% |
| Rhabdomyolysis |
6.0% |
| Muscle Haemorrhage |
4.0% |
| Overdose |
4.0% |
| Syncope |
4.0% |
| Vomiting |
4.0% |
| Dyspnoea |
3.3% |
| Electrocardiogram Qt Prolonged |
3.3% |
| Rectal Haemorrhage |
3.3% |
| Renal Failure |
3.3% |
| Atrial Fibrillation |
2.7% |
| Hyperphosphataemia |
2.7% |
| Labile Blood Pressure |
2.7% |
| Prothrombin Time Shortened |
2.7% |
| Renal Failure Acute |
2.7% |
| Tremor |
2.7% |
| Ventricular Fibrillation |
2.7% |
| Blood Creatine Phosphokinase Increased |
2.0% |
|
